Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia

Author： Klisovic Rebecca B.   Blum William   Liu Zhongfa   Xie Zhiliang   Kefauver Cheryl   Huynh Lenguyen   Zwiebel James A.   Devine Steven M.   Byrd John C.   Grever Michael R.   Chan Kenneth K.   Marcucci Guido  

Publisher： Informa Healthcare

ISSN： 1042-8194

Source： Leukemia and Lymphoma, Vol.55, Iss.6, 2014-06, pp. : 1332-1336

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia

By Walker Alison R.   Klisovic Rebecca B.   Garzon Ramiro   Schaaf Larry J.   Humphries Kristina   Devine Steven M.   Byrd John C.   Grever Michael R.   Marcucci Guido   Blum William  

Leukemia and Lymphoma, Vol. 55, Iss. 6, 2014-06 ,pp. : 1304-1308

Informa Healthcare

Access to resources Recommend Favorite

High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study

By Tedeschi Alessandra   Montillo Marco   Strocchi Elena   Cafro Anna   Tresoldi Elisabetta   Intropido Liliana   Nichelatti Michele   Marbello Laura   Baratè Claudia   Camaggi Carlo   Morra Enrica  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 6, 2007-06 ,pp. : 771-779

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacokinetics of high-dose simvastatin in refractory and relapsed chronic lymphocytic leukemia patients

By Ahmed Tamer   Hayslip John   Leggas Markos  

Cancer Chemotherapy and Pharmacology, Vol. 72, Iss. 6, 2013-12 ,pp. : 1369-1374

Springer Publishing Company

Access to resources Recommend Favorite

Efficacy of tosedostat, a novel, oral agent for elderly patients with relapsed or refractory acute myeloid leukemia: a review of the Phase II OPAL trial

By Mathisen Michael S   Ravandi Farhad  

Future Oncology, Vol. 8, Iss. 4, 2012-04 ,pp. : 351-357

Future Medicine

Access to resources Recommend Favorite

Dexamethasone, High-Dose Cytarabine, and Cisplatin in Combination with Rituximab as Salvage Treatment for Patients with Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

By Mey Ulrich   Orlopp Katjana   Flieger Dimitri   Strehl John   Ho Anthony   Hensel Manfred   Bopp Cordula   Gorschlüter Marcus   Wilhelm Martin   Birkmann Josef   Kaiser Ulrich   Neubauer Andreas   Florschütz Axel   Rabe Christian   Hahn Corinna   Glasmacher Axel   Schmidt-Wolf Ingo  

Cancer Investigation, Vol. 24, Iss. 6, 2006-09 ,pp. : 593-600

Informa Healthcare

Access to resources Recommend Favorite